Begin main content

Therapeutic Review of Third-Line Drugs for Type 2 Diabetes — An Update

January 26, 2018
In 2017, CADTH began preliminary work on a Therapeutic Review to assess new third-line drug therapies for type 2 diabetes and provide recommendations on their optimal use. The drugs included in this review included dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, and sodium-glucose cotransporter-2 inhibitors. In January 2018...

Call for Patient Input: Orkambi

January 24, 2018
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website. Orkambi Brand name Generic name Manufacturer I...

Call for Patient Input: Taltz

January 17, 2018
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website. Taltz Brand name Generic name Manufacturer Ind...

Patient Input ― An Integral Part of the 2018 CADTH Symposium

January 16, 2018
Given the theme of the 2018 CADTH Symposium ― Managing Health Technologies: Supporting Appropriate, Affordable, and Accessible Care ― which relates so directly to patients, CADTH is very pleased that our conference is once again officially accredited by Patients Included. The annual CADTH Symposium is a must-attend health policy event that bring...

New at CADTH — January 2018

January 11, 2018
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.